LIVIVO - Search results -

Search results

Result 1 - 10 of total 184

Search options

Article ; Online: Systematic review and meta-analysis on the safety of dalbavancin.

Monteagudo-Martínez, N / Solís-García Del Pozo, J / Ikuta, Ichiro / Galindo, Mf / Jordán, J

2021 Volume 20, Issue 9, Page(s) 1095–1107

Abstract: Background: Dalbavancin is a semisynthetic lipoglycopeptide antimicrobial agent with activity against Gram-positive bacteria including anaerobes.: Research design and methods: Meta-analysis of randomized control trials and large case series (more ... ...

Abstract	Background: Dalbavancin is a semisynthetic lipoglycopeptide antimicrobial agent with activity against Gram-positive bacteria including anaerobes. Research design and methods: Meta-analysis of randomized control trials and large case series (more than 20 patients), were identified by searching Pubmed and Cochrane databases through 14 December 2020. Results: 3,073 patients from 6 RCTs met the inclusion criteria. Treatment emergent adverse effects were described in 30.6% dalbavancin patients, and 38.1% patients with other treatments. Our meta-analysis supports favorable results for dalbavancin treatment (OR 0.79; 95%CI 0.66-0.94; p = 0.01). 2.74% dalbavancin patients had to discontinue treatment versus 2.49% patients on other antibiotics. 4.80% dalbavancin patients versus 5.30% patients with other treatments had severe adverse events. 0.31% in the dalbavancin group and 0.95% receiving other antibiotics died. There was no statistically significant difference in severe adverse effects with OR 0.77; 95% CI 0.52-1.14; p = 0.19. Dalbavancin therapy was shown to have statistically significant lower mortality rate (OR 0.26; 95% CI 0.07-0.90; p = 0.03). Observational studies reported few side effects but included a heterogeneous population of patients concerning their diagnosis and the duration of antibiotic treatment. Conclusions: Dalbavancin has comparable safety profile relative to other antibiotics and is well-tolerated.
MeSH term(s)	Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/adverse effects ; Gram-Positive Bacteria/drug effects ; Gram-Positive Bacteria/isolation & purification ; Gram-Positive Bacterial Infections/drug therapy ; Gram-Positive Bacterial Infections/microbiology ; Humans ; Randomized Controlled Trials as Topic ; Teicoplanin/administration & dosage ; Teicoplanin/adverse effects ; Teicoplanin/analogs & derivatives
Chemical Substances	Anti-Bacterial Agents ; Teicoplanin (61036-62-2) ; dalbavancin (808UI9MS5K)
Language	English
Publishing date	2021-06-07
Publishing country	England
Document type	Comparative Study ; Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	2088728-0
ISSN	1744-764X ; 1474-0338
ISSN (online)	1744-764X
ISSN	1474-0338
DOI	10.1080/14740338.2021.1935864
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6096: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Is Satoyoshi syndrome an autoimmune disease? A systematic review.

Viana Abreu Montanaro, Vinícius / Solís-García Del Pozo, Julián / Falcão Hora, Thiago / León, Beatriz H / de Cabo, Carlos / Solera, Javier

Rheumatology (Oxford, England)

2023 Volume 62, Issue 7, Page(s) 2343–2351

Abstract: Objectives: Satoyoshi syndrome is a rare multisystem disease of presumed autoimmune aetiology. We carried out a systematic review to evaluate the available evidence to support that autoimmune hypothesis.: Methods: We searched for Satoyoshi syndrome ... ...

Abstract	Objectives: Satoyoshi syndrome is a rare multisystem disease of presumed autoimmune aetiology. We carried out a systematic review to evaluate the available evidence to support that autoimmune hypothesis. Methods: We searched for Satoyoshi syndrome cases in PubMed, the Web of Science and Scopus up to January 2022, using keywords 'Satoyoshi syndrome' or 'Komuragaeri disease'. Data on symptoms, associated autoimmune diseases, presence of autoantibodies and response to treatment were collected. Results: A total of 77 patients from 57 articles published between 1967 and 2021 were included; 59 patients were women. The mean age at diagnosis was 21.2 years. All cases had painful muscular spasms and alopecia. Frequent manifestations included: diarrhoea, malabsorption, growth retardation, amenorrhoea and bone deformity. Satoyoshi syndrome was associated with other autoimmune diseases: myasthenia gravis, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, atopic dermatitis, bronchial and lupus erythematosus. Autoantibody determinations were performed in 39 patients, of which 27 had positive results. The most frequently detected autoantibodies were ANAs. Other less frequently found autoantibodies were: anti-acetylcholine receptor antibodies, anti-DNA antibodies, antithyroid antibodies, anti-glutamic acid decarboxylase (anti-GAD) and anti-gliadin antibodies. Pharmacological treatment was reported in 50 patients. Most of them improved with CS, immunosuppressants and immunoglobulins, or a combination of these medications. Conclusion: Satoyoshi syndrome is associated with other autoimmune diseases and a variety of autoantibodies. Improvement after CS or other immunosuppressant treatment was observed in 90% of cases. These data support an autoimmune aetiology for Satoyoshi syndrome. More studies including systematic determination of autoantibodies in all patients with Satoyoshi syndrome will help us advance in our understanding of this disease.
MeSH term(s)	Humans ; Female ; Young Adult ; Adult ; Male ; Spasm/complications ; Spasm/diagnosis ; Spasm/drug therapy ; Alopecia/diagnosis ; Alopecia/etiology ; Alopecia/drug therapy ; Autoimmune Diseases/complications ; Myasthenia Gravis ; Autoantibodies ; Immunosuppressive Agents/therapeutic use ; Diarrhea
Chemical Substances	Autoantibodies ; Immunosuppressive Agents
Language	English
Publishing date	2023-02-07
Publishing country	England
Document type	Systematic Review ; Journal Article
ZDB-ID	1464822-2
ISSN	1462-0332 ; 1462-0324
ISSN (online)	1462-0332
ISSN	1462-0324
DOI	10.1093/rheumatology/kead067
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 240: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 497: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients.

Solis-García Del Pozo, J / Galindo, M F / Nava, E / Jordán, J

European review for medical and pharmacological sciences

2020 Volume 24, Issue 13, Page(s) 7475–7484

Abstract: The pandemic caused by the new SARS-CoV2 coronavirus has led to an effort to find treatments that are effective against this disease that the World Health Organization calls COVID-19. In severe cases of COVID-19, there is an increase in cytokines, among ... ...

Abstract	The pandemic caused by the new SARS-CoV2 coronavirus has led to an effort to find treatments that are effective against this disease that the World Health Organization calls COVID-19. In severe cases of COVID-19, there is an increase in cytokines, among which IL-6 seems to play an important role. A search has been performed for studies using IL-6 blocking drugs (tocilizumab, siltuximab, and sarilumab) in PubMed, Web of Science, and Scopus. Also, a search of ongoing trials registered at clinicaltrials.gov was performed. We found very little published clinical experience with these drugs, consisting mainly of case reports or case series with few patients. The results of clinical trials are necessary to clarify the role of these drugs in patients with COVID-19.
MeSH term(s)	Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal, Humanized/pharmacology ; Antiviral Agents/pharmacology ; Betacoronavirus/drug effects ; Betacoronavirus/immunology ; COVID-19 ; Coronavirus Infections/diagnosis ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Humans ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/immunology ; Pandemics/prevention & control ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; SARS-CoV-2
Chemical Substances	Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antiviral Agents ; Interleukin-6 ; tocilizumab (I031V2H011) ; sarilumab (NU90V55F8I) ; siltuximab (T4H8FMA7IM)
Keywords	covid19
Language	English
Publishing date	2020-07-15
Publishing country	Italy
Document type	Journal Article ; Systematic Review
ZDB-ID	605550-3
ISSN	2284-0729 ; 1128-3602 ; 0392-291X
ISSN (online)	2284-0729
ISSN	1128-3602 ; 0392-291X
DOI	10.26355/eurrev_202007_21916
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1887: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review.

Solís-García Del Pozo, Julián / de Cabo, Carlos / Solera, Javier

Orphanet journal of rare diseases

2020 Volume 15, Issue 1, Page(s) 115

Abstract: Background: Satoyoshi syndrome (SS) [OMIM 600705; ORFHA 3130] is a multisystemic disease with a probable autoimmune basis, whose main symptoms are muscle spasms, alopecia, diarrhea and skeletal alterations. Chronic diarrhea may be severe and result in ... ...

Abstract	Background: Satoyoshi syndrome (SS) [OMIM 600705; ORFHA 3130] is a multisystemic disease with a probable autoimmune basis, whose main symptoms are muscle spasms, alopecia, diarrhea and skeletal alterations. Chronic diarrhea may be severe and result in malnutrition, anemia, growth retardation, cachexia, disability and even death. However, to date, no review of the digestive symptoms has been carried out. Methods: A search was performed in MEDLINE, Scopus and Web of Science databases. Cases of SS, without language or date restrictions, were recorded. Sixty-seven cases of SS were found up until December 2019. Thirty-nine cases described gastrointestinal manifestations. Results: Chronic diarrhea was the main digestive symptom (92.3%). Other symptoms such as abdominal pain (15.4%), nausea (7.7%) and vomiting (7.7%), were less frequent. The D-xylose test was positive in 10 out of 12 patients, and 9 out of 13 cases showed a flattened oral glucose tolerance test suggesting carbohydrate malabsorption. Antinuclear antibodies were detected in 8 out of 16 cases. Antibodies to stomach or duodenum tissue lysates were also detected by Western blot. Histological data revealed predominantly lymphoplasmacytic inflammatory infiltrate that can affect any section of the digestive tract. In 6 out of 10 patients, diarrhea improved with a treatment regimen that included corticosteroids. Other treatments, such as methotrexate, carbohydrate restricted diets or otilonium bromide, improved digestive symptoms in isolated patients. Improvement of symptoms up to three years of follow-up has been described. None of the three patients who died had received corticosteroids or immunosuppressants. Conclusion: Chronic diarrhea with malabsorption is one of the most disabling symptoms in SS. The early recognition of this disease is essential for immunosuppressive treatment and a better outcome.
MeSH term(s)	Alopecia ; Bone and Bones/abnormalities ; Diarrhea/drug therapy ; Gastrointestinal Tract ; Humans ; Spasm
Language	English
Publishing date	2020-05-19
Publishing country	England
Document type	Journal Article ; Review ; Systematic Review
ISSN	1750-1172
ISSN (online)	1750-1172
DOI	10.1186/s13023-020-01395-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Estudio de la incidencia de COVID-19 en España y su relación geográfica provincial.

Alfaro-Martínez, J J / Solís García Del Pozo, J / Quílez Toboso, R P / García Blasco, L / Rosa Felipe, C

Journal of healthcare quality research

2023 Volume 38, Issue 5, Page(s) 299–303

Abstract: Background: The aim of this study was to determine incidence of COVID-19 in relationship to geographical distribution among Spain.: Method: Cluster analysis taking into consideration the incidence of COVID-19 in the provinces and autonomous cities of ...

Title translation	Study of incidence of COVID-19 in Spain and its relationship to geographical province distribution.
Abstract	Background: The aim of this study was to determine incidence of COVID-19 in relationship to geographical distribution among Spain. Method: Cluster analysis taking into consideration the incidence of COVID-19 in the provinces and autonomous cities of Spain in each of the first six waves of the pandemic. Results: All the provinces of the Canary Islands, Catalonia and Andalusia form independent clusters. In Comunidad Valenciana, Galicia, País Vasco and Aragón two out of three provinces (three out of four in Galicia) were in the same cluster, with no other provinces. Discussion: The incidence of COVID-19 in Spain in the first six waves forms clusters that reproduce the territorial division of Spain into autonomous communities. Although this could be explained by greater mobility within a community, it cannot be ruled out that this distribution is due to differences in screening, diagnosis, registration or reporting of COVID-19 cases.
MeSH term(s)	Humans ; Spain/epidemiology ; COVID-19/epidemiology ; Incidence
Language	Spanish
Publishing date	2023-02-14
Publishing country	Spain
Document type	English Abstract ; Journal Article
ISSN	2603-6479
ISSN (online)	2603-6479
DOI	10.1016/j.jhqr.2023.02.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Treatment of Satoyoshi syndrome: a systematic review.

Solís-García Del Pozo, Julián / de Cabo, Carlos / Solera, Javier

Orphanet journal of rare diseases

2019 Volume 14, Issue 1, Page(s) 146

Abstract: Background: Satoyoshi syndrome is a multisystemic rare disease of unknown etiology, although an autoimmune basis is presumed. Its main symptoms are: painful muscle spasms, diarrhea, alopecia and skeletal abnormalities. Clinical course without treatment ... ...

Abstract	Background: Satoyoshi syndrome is a multisystemic rare disease of unknown etiology, although an autoimmune basis is presumed. Its main symptoms are: painful muscle spasms, diarrhea, alopecia and skeletal abnormalities. Clinical course without treatment may result in serious disability or death. A review of treatment and its response is still pending. Results: Sixty-four cases of Satoyoshi syndrome were published between 1967 and 2018. 47 cases described the treatment administered. Drugs used can be divided into two main groups of treatment: muscle relaxants/anticonvulsants, and corticosteroids/immunosuppressants. Dantrolene improved muscle symptoms in 13 out of 15 cases, but not any other symptoms of the disease. Other muscle relaxants or anticonvulsant drugs showed little or no effect. 28 out of 30 cases responded to a regimen that included costicosteroids. Other immunosuppressive drugs including cyclosporine, mycophenolate mofetil, azathioprine, methotrexate, tacrolimus and cyclophosphamide were used to decrease corticosteroid dose or improve efficacy. Immunoglobulin therapy was used in nine patients and four of them obtained a favorable response. Conclusion: Corticosteroids was the most widely treatment employed with the best results in Satoyoshi syndrome. Further studies are needed to determine optimal dose and duration of corticosteroids as well as the role of other immunosuppressants and immunoglobulin therapy. Genetic or autoimmune markers will be useful to guide future therapies.
MeSH term(s)	Adrenal Cortex Hormones/therapeutic use ; Alopecia/drug therapy ; Animals ; Anticonvulsants/therapeutic use ; Bone and Bones/abnormalities ; Dantrolene/therapeutic use ; Diarrhea/drug therapy ; Female ; Humans ; Immunization, Passive ; Immunosuppressive Agents/therapeutic use ; Male ; Rare Diseases/drug therapy ; Spasm/drug therapy
Chemical Substances	Adrenal Cortex Hormones ; Anticonvulsants ; Immunosuppressive Agents ; Dantrolene (F64QU97QCR)
Language	English
Publishing date	2019-06-19
Publishing country	England
Document type	Journal Article ; Review ; Systematic Review
ZDB-ID	2225857-7
ISSN	1750-1172 ; 1750-1172
ISSN (online)	1750-1172
ISSN	1750-1172
DOI	10.1186/s13023-019-1120-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients

Solis-García Del Pozo, J / Galindo, M F / Nava, E / Jordán, J

Eur Rev Med Pharmacol Sci

Abstract	The pandemic caused by the new SARS-CoV2 coronavirus has led to an effort to find treatments that are effective against this disease that the World Health Organization calls COVID-19. In severe cases of COVID-19, there is an increase in cytokines, among which IL-6 seems to play an important role. A search has been performed for studies using IL-6 blocking drugs (tocilizumab, siltuximab, and sarilumab) in PubMed, Web of Science, and Scopus. Also, a search of ongoing trials registered at clinicaltrials.gov was performed. We found very little published clinical experience with these drugs, consisting mainly of case reports or case series with few patients. The results of clinical trials are necessary to clarify the role of these drugs in patients with COVID-19.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #676741
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: La aplicación de las órdenes de no reanimación y la limitación del esfuerzo terapéutico en pacientes ingresados en Medicina Interna en un hospital comarcal.

Solís-García del Pozo, J / Gómez-Pérez, I

Revista de calidad asistencial : organo de la Sociedad Espanola de Calidad Asistencial

2013 Volume 28, Issue 1, Page(s) 50–55

Abstract: Objectives: To determine the practice and associated factors of limiting therapeutic effort and do not resuscitate (DNR) order in a general Internal Medicine ward in a regional hospital.: Material and methods: A retrospective search was performed to ... ...

Title translation	The application of do not resuscitate orders and withholding treatment in patients admitted to Internal Medicine in a first level hospital.
Abstract	Objectives: To determine the practice and associated factors of limiting therapeutic effort and do not resuscitate (DNR) order in a general Internal Medicine ward in a regional hospital. Material and methods: A retrospective search was performed to find patients who received do not resuscitate orders and patients who died, among those admitted to Internal Medicine between January and May 2011 at the Hospital of Villarrobledo. The limitation in therapeutic effort (LTE) in this group is described. Results: A total of 106 cases were analyzed, 80 of them received DNR (10.28% of admissions during this period). Fifty four patients received other LTE. The information on the reasons and communication with the patient and family was incomplete in most cases. No differences were found between patients who died with and without LTE or with and without DNR orders. Conclusions: The information on the reasons that lead to LTE/DNR orders decisions should be improved, as well as the information on the people involved in these decisions.
MeSH term(s)	Aged, 80 and over ; Female ; Hospitals ; Humans ; Internal Medicine ; Male ; Patient Admission ; Resuscitation Orders ; Retrospective Studies ; Withholding Treatment/statistics & numerical data
Language	Spanish
Publishing date	2013-01
Publishing country	Spain
Document type	English Abstract ; Journal Article
ISSN	1887-1364
ISSN (online)	1887-1364
DOI	10.1016/j.cali.2012.09.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Are there differences between ceftolozane/tazobactam and ceftazidime/avibactam in treating patients with complicated abdominal infections? Evidence from clinical trials.

Avilés Martínez, M C / Alfaro Martínez, J J / Blanch Sancho, J J / Solís García Del Pozo, J

Journal of chemotherapy (Florence, Italy)

2022 Volume 34, Issue 7, Page(s) 419–426

Abstract: Ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (CZA) are new possibilities of antimicrobial treatment that combined a β-lactam with a β-lactamase inhibitor. The United States (US) and European regulatory agencies approved their clinical use in ... ...

Abstract	Ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (CZA) are new possibilities of antimicrobial treatment that combined a β-lactam with a β-lactamase inhibitor. The United States (US) and European regulatory agencies approved their clinical use in adults with complicated intra-abdominal infections. This study aims to know if one of the two antibiotics obtain better efficacy in adults with complicated intra-abdominal infections and by specific pathogens such as
MeSH term(s)	Adult ; Humans ; Ceftazidime/therapeutic use ; Ceftazidime/pharmacology ; beta-Lactamase Inhibitors/therapeutic use ; Meropenem/pharmacology ; Escherichia coli ; Azabicyclo Compounds/therapeutic use ; Azabicyclo Compounds/pharmacology ; Cephalosporins/therapeutic use ; Cephalosporins/pharmacology ; Tazobactam/therapeutic use ; Tazobactam/pharmacology ; Intraabdominal Infections/drug therapy ; Drug Combinations ; Anti-Bacterial Agents/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Pseudomonas aeruginosa ; Microbial Sensitivity Tests ; Pseudomonas Infections/drug therapy
Chemical Substances	avibactam, ceftazidime drug combination ; Ceftazidime (9M416Z9QNR) ; avibactam (7352665165) ; ceftolozane (37A4IES95Q) ; beta-Lactamase Inhibitors ; Meropenem (FV9J3JU8B1) ; Azabicyclo Compounds ; Cephalosporins ; ceftolozane, tazobactam drug combination ; Tazobactam (SE10G96M8W) ; Drug Combinations ; Anti-Bacterial Agents
Language	English
Publishing date	2022-05-13
Publishing country	England
Document type	Journal Article
ZDB-ID	1036294-0
ISSN	1973-9478 ; 1120-009X
ISSN (online)	1973-9478
ISSN	1120-009X
DOI	10.1080/1120009X.2022.2073160
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2701: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 387: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis.

Monteagudo-Martínez, Nuria / Solís-García Del Pozo, Julián / Nava, Eduardo / Ikuta, Ichiro / Galindo, Maria / Jordán, Joaquin

Expert review of anti-infective therapy

2020 Volume 20, Issue 11, Page(s) 1477–1489

Abstract: Objectives: To know the efficacy of different doses of dalbavancin in acute bacterial skin and skin-structure infections (ABSSSIs) and versus other antibiotics.: Methods: We performed a systematic review of dalbavancin efficacy for ABSSSIs. We ... ...

Abstract	Objectives: To know the efficacy of different doses of dalbavancin in acute bacterial skin and skin-structure infections (ABSSSIs) and versus other antibiotics. Methods: We performed a systematic review of dalbavancin efficacy for ABSSSIs. We selected 10 clinical trials from MEDLINE and Cochrane databases for qualitative review. Of these, five trials compared one or two doses of dalbavancin versus other antibiotics such as vancomycin or linezolid. Results: Treatment outcomes with other antibiotics were not significantly different versus two doses of dalbavancin (OR 1.13; 95% CI 0.75-1.71; p = 0.55) or single dose dalbavancin (OR 0.98; 95% CI 0.19-5.17; p = 0.98). One dose versus two doses of dalbavancin did not show significant differences in any of the treatment groups. In contrast, the global microbiological assessment results indicated a favorable outcome for two doses of dalbavancin compared to the single dose of dalbavancin (OR 2.96; 95% CI 1.19-7.39; p = 0.02) in both methicillin-resistant and methicillin-susceptible Conclusion: Either single dose or two dose dalbavancin treatment is as clinically effective as other antibiotics such as vancomycin and linezolid for the treatment of ABSSSIs.
MeSH term(s)	Humans ; Vancomycin/pharmacology ; Vancomycin/therapeutic use ; Linezolid/therapeutic use ; Methicillin-Resistant Staphylococcus aureus ; Methicillin/pharmacology ; Methicillin/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Skin Diseases, Bacterial/drug therapy ; Skin Diseases, Bacterial/microbiology ; Staphylococcus aureus ; Penicillins ; Anti-Infective Agents/pharmacology
Chemical Substances	dalbavancin (808UI9MS5K) ; Vancomycin (6Q205EH1VU) ; Linezolid (ISQ9I6J12J) ; Methicillin (Q91FH1328A) ; Anti-Bacterial Agents ; Penicillins ; Anti-Infective Agents
Language	English
Publishing date	2020-10-21
Publishing country	England
Document type	Meta-Analysis ; Systematic Review ; Journal Article
ZDB-ID	2181279-2
ISSN	1744-8336 ; 1478-7210
ISSN (online)	1744-8336
ISSN	1478-7210
DOI	10.1080/14787210.2021.1828865
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6106: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito